The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor

被引：0
|
作者：
Nenad Sarapa
Margaret R. Britto
Michelle B. Mainka
Kourosh Parivar
机构：
[1] Clinical PK/PD,Pfizer Global Research & Development
[2] Clinical Pharmacology,Quintiles Inc.
[3] Statistics and Programming,Pfizer Global Research & Development
来源：
European Journal of Clinical Pharmacology | 2005年 / 61卷
关键词：
Valdecoxib; Pharmacokinetics; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 256
页数：9
相关论文
共 50 条
  • [41] No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
    Karin Wåhlander
    Maria Eriksson-Lepkowska
    Lars Frison
    Gunnar Fager
    Ulf G. Eriksson
    Clinical Pharmacokinetics, 2003, 42 (8) : 755 - 764
  • [42] Pharmacokinetics of the novel COX-2 selective inhibitor vitacoxib in cats: The effects of feeding and dose
    Wang, Jianzhong
    Gong, Xiaohui
    Xue, Jiao
    Zhang, Suxia
    Li, Jing
    Cao, Xingyuan
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2019, 42 (03) : 294 - 299
  • [43] Clinical pharmacology of the selective COX-2 inhibitor
    Burian, M
    Geisslinger, G
    ORTHOPADE, 2003, 32 (12): : 1078 - +
  • [44] Etoricoxib: A highly selective COX-2 inhibitor
    Martina, SD
    Vesta, KS
    Ripley, TL
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (05) : 854 - 862
  • [45] Rofecoxib: A selective and effective COX-2 inhibitor
    不详
    Drugs & Therapy Perspectives, 2002, 18 (2) : 1 - 3
  • [46] Etodolac: An overview of a selective COX-2 inhibitor
    Jones R.A.
    InflammoPharmacology, 1999, 7 (3) : 269 - 275
  • [47] NSAIDs: gastroprotection or selective COX-2 inhibitor?
    Dickman, A
    Ellershaw, J
    PALLIATIVE MEDICINE, 2004, 18 (04) : 275 - 286
  • [48] FTY720 pharmacokinetics in mild to moderate hepatic impairment.
    Kovarik, JM
    Schmouder, RL
    Serra, D
    Wang, Y
    Lasseter, K
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 473 - 473
  • [49] The Effects of Mild or Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naloxegol
    Bui, Khanh
    She, Fahua
    Sostek, Mark
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (12): : 1368 - 1374
  • [50] Withdrawal of cox-2 inhibitor rofecoxib and valdecoxib: Impact on NSAID and PPI prescriptions and expenditures
    Sun, SX
    Lee, KY
    Bertram, CT
    VALUE IN HEALTH, 2006, 9 (03) : A28 - A28
12345